{
    "root": "11b7dcc4-7810-4ecd-b203-3dc5d350743b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Adalimumab",
    "value": "20241121",
    "ingredients": [
        {
            "name": "ADALIMUMAB",
            "code": "FYS6T7F842"
        },
        {
            "name": "ADIPIC ACID",
            "code": "76A0JE0FKJ"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "adalimumab-adaz tumor necrosis factor ( tnf ) -blocker indicated : \u2022 rheumatoid arthritis ( rheumatoid arthritis ) ( 1.1 ) : reducing signs symptoms , inducing major response , inhibiting progression structural damage , improving physical function adult patients moderately severely active rheumatoid arthritis . \u2022 juvenile idiopathic arthritis ( jia ) ( 1.2 ) : reducing signs symptoms moderately severely active polyarticular jia patients 2 years age older . \u2022 psoriatic arthritis ( psa ) ( 1.3 ) : reducing signs symptoms , inhibiting progression structural damage , improving physical function adult patients active psa . \u2022 ankylosing spondylitis ( ) ( 1.4 ) : reducing signs symptoms adult patients active . \u2022 crohn \u2019 disease ( cd ) ( 1.5 ) : treatment moderately severely active crohn \u2019 disease adults pediatric patients 6 years age older . \u2022 ulcerative colitis ( uc ) ( 1.6 ) : treatment moderately severely active ulcerative colitis adult patients . limitations : effectiveness established patients lost response intolerant tnf blockers . \u2022 plaque psoriasis ( ps ) ( 1.7 ) : treatment adult patients moderate severe chronic plaque psoriasis candidates systemic therapy phototherapy , systemic therapies medically less appropriate . \u2022 hidradenitis suppurativa ( hs ) ( 1.8 ) : treatment moderate severe hidradenitis suppurativa adult patients . \u2022 uveitis ( uv ) ( 1.9 ) : treatment non-infectious intermediate , posterior , panuveitis adult patients .",
    "contraindications": "\u2022 administer subcutaneous injection ( 2 ) rheumatoid arthritis , psoriatic arthritis , ankylosing spondylitis ( 2.1 ) : \u2022 adults : 40 mg every week . \u2022 patients rheumatoid arthritis receiving methotrexate may benefit increasing 40 mg every week 80 mg every week . juvenile idiopathic arthritis ( 2.2 ) : pediatric weight 2 years age older recommended 10 kg ( 22 lbs ) less 15 kg ( 33 lbs ) 10 mg every week 15 kg ( 33 lbs ) less 30 kg ( 66 lbs ) 20 mg every week 30 kg ( 66 lbs ) greater 40 mg every week crohn 's disease ( 2.3 ) : \u2022 adults : 160 mg day 1 ( given one day split two consecutive days ) ; 80 mg day 15 ; 40 mg every week starting day 29 . \u2022 pediatric patients 6 years age older : pediatric weight recommended days 1 15 starting day 29 17 kg ( 37 lbs ) less 40 kg ( 88 lbs ) day 1 : 80 mg day 15 : 40 mg 20 mg every week 40 kg ( 88 lbs ) greater day 1 : 160 mg ( single dose split two consecutive days ) day 15 : 80 mg 40 mg every week ulcerative colitis ( 2.4 ) : \u2022 adults : 160 mg day 1 ( given one day split two consecutive days ) , 80 mg day 15 40 mg every week starting day 29. discontinue patients without evidence remission eight weeks ( day 57 ) . plaque psoriasis adult uveitis ( 2.5 ) : \u2022 adults : 80 mg initial dose , followed 40 mg every week starting one week initial dose . hidradenitis suppurativa ( 2.6 ) : \u2022 adults : \u2022 day 1 : 160 mg ( given one day split two consecutive days ) \u2022 day 15 : 80 mg \u2022 day 29 subsequent doses : 40 mg every week 80 mg every week",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "Adalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: \u2022 Rheumatoid Arthritis (RA) (1.1) : reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. \u2022 Juvenile Idiopathic Arthritis (JIA) (1.2) : reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. \u2022 Psoriatic Arthritis (PsA) (1.3) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. \u2022 Ankylosing Spondylitis (AS) (1.4) : reducing signs and symptoms in adult patients with active AS. \u2022 Crohn\u2019s Disease (CD) (1.5) : treatment of moderately to severely active Crohn\u2019s disease in adults and pediatric patients 6 years of age and older. \u2022 Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. \u2022 Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. \u2022 Hidradenitis Suppurativa (HS) ( 1.8 ) : treatment of moderate to severe hidradenitis suppurativa in adult patients. \u2022 Uveitis (UV) ( 1.9 ) : treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.",
    "contraindications_original": "\u2022 Administer by subcutaneous injection (2) Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (2.1) : \u2022 Adults: 40 mg every other week. \u2022 Some patients with RA not receiving methotrexate may benefit from increasing the dosage to 40 mg every week or 80 mg every other week. Juvenile Idiopathic Arthritis (2.2) : Pediatric Weight 2 Years of Age and Older Recommended Dosage 10\u00a0kg (22\u00a0lbs) to less than 15\u00a0kg (33\u00a0lbs) 10\u00a0mg every other week 15\u00a0kg (33\u00a0lbs) to less than 30\u00a0kg (66\u00a0lbs) 20\u00a0mg every other week 30\u00a0kg (66\u00a0lbs) and greater 40\u00a0mg every other week Crohn's Disease (2.3 ): \u2022 Adults: 160 mg on Day 1 (given in one day or split over two consecutive days); 80 mg on Day 15; and 40 mg every other week starting on Day 29. \u2022 Pediatric Patients 6 Years of Age and Older: Pediatric Weight Recommended Dosage Days 1 and 15 Starting on Day 29 17 kg (37 lbs) to less than 40 kg (88 lbs) Day 1: 80 mg Day 15: 40 mg 20 mg every other week 40\u00a0kg (88\u00a0lbs) and greater Day 1: 160\u00a0mg (single dose or split over two consecutive days) Day 15: 80\u00a0mg 40\u00a0mg every other week Ulcerative Colitis (2.4 ): \u2022 Adults : 160\u00a0mg on Day 1 (given in one day or split over two consecutive days), 80\u00a0mg on Day 15 and 40\u00a0mg every other week starting on Day 29. Discontinue in patients without evidence of clinical remission by eight weeks (Day 57). Plaque Psoriasis or Adult Uveitis ( 2.5 ): \u2022 Adults : 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose. Hidradenitis Suppurativa ( 2.6 ): \u2022 Adults: \u2022 Day 1: 160 mg (given in one day or split over two consecutive days) \u2022 Day 15: 80 mg \u2022 Day 29 and subsequent doses: 40 mg every week or 80 mg every other week",
    "adverseReactions_original": "None."
}